Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by Xiawen13 on Jan 31, 2016 10:42am

Label

It seems the most likely label would be "cis containing, bcg refractory, unwilimg or unable to undergo cystecomy."

but the adcom seemed not to adress question 3a, therefore i didnt find trough the transcript a clear comment in favor of that label.  In their final decision adcom member only commented on the "unwiling or unable". M80 my question is WHY

also, a new chemotherapy "myocyclin" treatment just came out and have better effect on papilary cancer than BCG, so i think it supports my view on the CiS label

again m80, any comment?
Comment by Mackinnon80 on Jan 31, 2016 10:09pm
Xiamen, Myocyclin is an antiobiotic. It is use/used to treat infections. In fact, according to new studies, bladder cancer could be a side effect of taking myocyclin. From what I read, it's of no use to treat NMIBC patients. Please give us a link if you have something on this. Back to your question. True that question 3a was quickly discussed (page 200 of the transcript). Only Dr Agarwal ...more  
Comment by HighteawithIntrepid on Jan 31, 2016 10:39pm
Many Thanks. With our modern technology my view is to go to a 0 to 10 voting system. Surely to God we have moved beyond  yes or no and a third button that rarely sees the light of day.
Comment by Xiawen13 on Feb 01, 2016 8:35am
Thanks m80, here is the link for the chemo more effective than bcg. It seems to apply only to papilary, so i dont think this drug can replace bcg and mcna for the cis  https://www.renalandurologynews.com/bladder-cancer/chemohyperthermia-safe-effective-for-nmibc-adjuvant-treatment/article/467329/
Comment by Mackinnon80 on Feb 01, 2016 8:56am
That link referred to mitomycin C...not the same thing that what you wrote in your first post (minoclycin....an antiobiotic) ! Mitomycin C was the comparator in what was supposed to be the second phase 3 for MCNA. The recurrence-free survival (RFS) numbers cited are not that much impressive for papillary-only tumors. The difference with the BCG group (the comparator) was non-significant. Also ...more  
Comment by Hatchchat on Feb 01, 2016 9:44am
M80, what's your guess on mcap for your most probable narrowed indication (CIS-contaning disease patients who failed BCG that can't or won't undergo cystectomy)?
Comment by Mackinnon80 on Feb 01, 2016 1:10pm
Like many TST shareholders, I think our upside potential is limited on the TSX. The Toronto stock exchange is one of the worst place to be traded for a biotech that hopes to be fairly valued. PLI is the best example. In the first week of march, if the approval is for the CIS-containing disease population, I see a market cap anywhere between 300 to 600 millions Can. Quite frankly I would be ...more  
Comment by txbioinv on Feb 02, 2016 9:22am
m80, if you invest in biotech/pharma on a regular basis, all that's been in the news from the recent immunotherapy/oncology drug developments/approvals is EARLY APPROVAL, ON AVERAGE ONE MONTH; additionally recent interviews with FDA bosses have confirmed those actions/intentions.......................................maybe I am correct about our decision......just one day late. At worst, I hope ...more  
Comment by Mackinnon80 on Feb 02, 2016 9:30am
You might be right Txbioinv. All I know is no management would announced they have received a CRL letter at the start of the day like this. To be halted like that more than 3 weeks before the PDUFA date, I believe there is more chance to get good news than bad news. We'll see. M80
Comment by txbioinv on Feb 02, 2016 9:36am
M80, your correct, usually CRL news end of day, I've seen a few in the AM but it doesn't matter because it must be dealt with, good or bad. There's a damn drug shortage big time and MCNA is safe; if this is disapproved for any reason, time to raise hell, ........................my plan is waiting. GL longtimers
Comment by cndexpatman on Feb 02, 2016 9:42am
Well it's not approved so too bad for you and all of us that placed faith in a crappy management team that made AdComm seem like amateur hour. Really too bad.
Comment by Hatchchat on Feb 02, 2016 9:43am
do you now it's criminal to spread such "statements" as the truth if it's not true. can you prove it?
Comment by txbioinv on Feb 02, 2016 9:46am
And who are you talking to? be specific hatchit.
Comment by redatnight on Feb 02, 2016 9:44am
Hey cndex...you are one real buzz kill!
Comment by txbioinv on Feb 02, 2016 9:46am
I agree 100% on that. ..............
Comment by Hatchchat on Feb 02, 2016 9:48am
i'm talking to the guy claiming that the FDA did not approve it. if he can not prove this statement and does spread false information on purpose, it's a crime and illegal.
Comment by txbioinv on Feb 02, 2016 9:56am
hatch,..........yes, possible factual slander against company. That poster has been a two faced poster here all along, soft bashing along the way. There are people here with devious agendas,,,,,,,,sad but true. GL
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities